October 23, 2013
Swiss pharmaceutical titan Novartis AG suffered from a 22% sales dive year-on-year for its blockbuster blood pressure medicine Diovan (valsartan) in January-September 2013, plagued by generic competition in the US and Europe and a clinical trial scandal in Japan. Sales...read more